QuatRx Anticipates NDA Filing For Vaginal Atrophy Therapy Ophena In 2009/2010

The non-estrogen treatment for postmenopausal women is a potential blockbuster, CEO Zerbe tells “The Pink Sheet” DAILY.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet